Effects of orally administered OP-1206 α-CD with loxoprofen-Na on walking dysfunction in the rat neuropathic intermittent claudication model
An orally active prostaglandin E1 analogue, OP-1206 α-CD improves walking dysfunction in the rat spinal stenosis model. Loxoprofen-Na, a non-steroidal anti-inflammatory drug, is used to relieve chronic pain in patients with lumbar spinal canal stenosis. To determine whether the OP-1206 α-CD in combi...
Gespeichert in:
| Veröffentlicht in: | Prostaglandins, leukotrienes and essential fatty acids leukotrienes and essential fatty acids, 2003-10, Vol.69 (4), p.269-273 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 273 |
|---|---|
| container_issue | 4 |
| container_start_page | 269 |
| container_title | Prostaglandins, leukotrienes and essential fatty acids |
| container_volume | 69 |
| creator | Nakai, Katsuhiko Takenobu, Yoshifumi Takimizu, Hideyuki Akimaru, Shinji Ito, Hidenori Maegawa, Hitoshi Marsala, Martin Katsube, Nobuo |
| description | An orally active prostaglandin E1 analogue, OP-1206
α-CD improves walking dysfunction in the rat spinal stenosis model. Loxoprofen-Na, a non-steroidal anti-inflammatory drug, is used to relieve chronic pain in patients with lumbar spinal canal stenosis.
To determine whether the OP-1206
α-CD in combination with loxoprofen-Na could induce a greater therapeutical effect on walking dysfunction and spinal cord blood flow (SCBF) than OP-1206
α-CD treatment alone after chronic spinal stenosis in the rat.
Spinal stenosis was induced by placing two pieces of silicon rubber strips in the lumbar (L4 and L6) epidural space of rats. After surgery, walking function was measured using a treadmill apparatus and SCBF was measured using a laser-Doppler flow meter. Drugs were administered orally twice a day for 11 days from the day 3 post-surgery.
OP-1206
α-CD elicited a significant improvement of walking dysfunction on days 7 and 14 post-surgery and significantly increased spinal cord blood flow on day 15, whereas walking dysfunction and SCBF of rats treated with loxoprofen-Na alone remained unchanged. Combined treatment of OP-1206
α-CD with loxoprofen-Na did not provide additive therapeutical effect.
These results suggest that a significant improvement seen after OP-1206
α-CD treatment is primarily mediated by improvement of the local spinal cord blood flow. This effect is not ameliorated or potentiated by a combined treatment with loxoprofen-Na. |
| doi_str_mv | 10.1016/S0952-3278(03)00109-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73553173</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0952327803001091</els_id><sourcerecordid>73553173</sourcerecordid><originalsourceid>FETCH-LOGICAL-c391t-f50c708e3b42ec83d09ce79b055d2492e8b1dfd600a343f0a0a43dd848b5d30b3</originalsourceid><addsrcrecordid>eNqFkU1uFDEQhVuIiAyBI4C8AcGioWy3p7tXCA2BIEUECVhbbrvMGNz2xHYT5hAcJhfhTHRmRsmSVUml79XPe1X1hMIrCnT5-gv0gtWctd0L4C8BKPQ1vVctqOCsZh3j96vFLXJcPcz5BwAwSpsH1TFlPbSUt4vqz6m1qEsm0ZKYlPdboszogssFExpy8bmmDJbk73W9ekeuXFkTH3_HTYoWQ_1JkRjIlfI_XfhOzDbbKeji5p4LpKyRJFVIwCnFjSprp-f2PHZ0pWAoRHs1GafVTjBGg_5RdWSVz_j4UE-qb-9Pv67O6vOLDx9Xb89rzXtaaitAt9AhHxqGuuMGeo1tP4AQhjU9w26gxpolgOINt6BANdyYrukGYTgM_KR6vp87_3E5YS5ydFmj9ypgnLJsuRCctnwGxR7UKeac0MpNcqNKW0lB3uQgdznIG5MlcLnLQdJZ9_SwYBpGNHeqg_Ez8OwAqKyVt0kF7fIdJ9iSUiZm7s2ew9mOXw6TzNph0GhcmnOTJrr_nPIPmq2m1g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73553173</pqid></control><display><type>article</type><title>Effects of orally administered OP-1206 α-CD with loxoprofen-Na on walking dysfunction in the rat neuropathic intermittent claudication model</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Nakai, Katsuhiko ; Takenobu, Yoshifumi ; Takimizu, Hideyuki ; Akimaru, Shinji ; Ito, Hidenori ; Maegawa, Hitoshi ; Marsala, Martin ; Katsube, Nobuo</creator><creatorcontrib>Nakai, Katsuhiko ; Takenobu, Yoshifumi ; Takimizu, Hideyuki ; Akimaru, Shinji ; Ito, Hidenori ; Maegawa, Hitoshi ; Marsala, Martin ; Katsube, Nobuo</creatorcontrib><description>An orally active prostaglandin E1 analogue, OP-1206
α-CD improves walking dysfunction in the rat spinal stenosis model. Loxoprofen-Na, a non-steroidal anti-inflammatory drug, is used to relieve chronic pain in patients with lumbar spinal canal stenosis.
To determine whether the OP-1206
α-CD in combination with loxoprofen-Na could induce a greater therapeutical effect on walking dysfunction and spinal cord blood flow (SCBF) than OP-1206
α-CD treatment alone after chronic spinal stenosis in the rat.
Spinal stenosis was induced by placing two pieces of silicon rubber strips in the lumbar (L4 and L6) epidural space of rats. After surgery, walking function was measured using a treadmill apparatus and SCBF was measured using a laser-Doppler flow meter. Drugs were administered orally twice a day for 11 days from the day 3 post-surgery.
OP-1206
α-CD elicited a significant improvement of walking dysfunction on days 7 and 14 post-surgery and significantly increased spinal cord blood flow on day 15, whereas walking dysfunction and SCBF of rats treated with loxoprofen-Na alone remained unchanged. Combined treatment of OP-1206
α-CD with loxoprofen-Na did not provide additive therapeutical effect.
These results suggest that a significant improvement seen after OP-1206
α-CD treatment is primarily mediated by improvement of the local spinal cord blood flow. This effect is not ameliorated or potentiated by a combined treatment with loxoprofen-Na.</description><identifier>ISSN: 0952-3278</identifier><identifier>EISSN: 1532-2823</identifier><identifier>DOI: 10.1016/S0952-3278(03)00109-1</identifier><identifier>PMID: 12907137</identifier><language>eng</language><publisher>Kidlington: Elsevier Ltd</publisher><subject>Administration, Oral ; alpha-Cyclodextrins ; Alprostadil - administration & dosage ; Alprostadil - analogs & derivatives ; Alprostadil - pharmacology ; Animals ; Biological and medical sciences ; Cyclodextrins ; Disease Models, Animal ; Drug Therapy, Combination ; Fundamental and applied biological sciences. Psychology ; Intermittent claudication ; Intermittent Claudication - drug therapy ; Intermittent Claudication - physiopathology ; Loxoprofen-Na ; Male ; OP-1206 α-CD ; Phenylpropionates - administration & dosage ; Phenylpropionates - pharmacology ; Prostaglandins E, Synthetic - administration & dosage ; Prostaglandins E, Synthetic - pharmacology ; Rats ; Rats, Wistar ; Regional Blood Flow - drug effects ; Spinal canal Stenosis ; Spinal Cord - blood supply ; Spinal cord blood flow ; Spinal Stenosis - drug therapy ; Spinal Stenosis - physiopathology ; Vertebrates: endocrinology ; Walking</subject><ispartof>Prostaglandins, leukotrienes and essential fatty acids, 2003-10, Vol.69 (4), p.269-273</ispartof><rights>2003 Elsevier Science Ltd</rights><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c391t-f50c708e3b42ec83d09ce79b055d2492e8b1dfd600a343f0a0a43dd848b5d30b3</citedby><cites>FETCH-LOGICAL-c391t-f50c708e3b42ec83d09ce79b055d2492e8b1dfd600a343f0a0a43dd848b5d30b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0952327803001091$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15261125$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12907137$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nakai, Katsuhiko</creatorcontrib><creatorcontrib>Takenobu, Yoshifumi</creatorcontrib><creatorcontrib>Takimizu, Hideyuki</creatorcontrib><creatorcontrib>Akimaru, Shinji</creatorcontrib><creatorcontrib>Ito, Hidenori</creatorcontrib><creatorcontrib>Maegawa, Hitoshi</creatorcontrib><creatorcontrib>Marsala, Martin</creatorcontrib><creatorcontrib>Katsube, Nobuo</creatorcontrib><title>Effects of orally administered OP-1206 α-CD with loxoprofen-Na on walking dysfunction in the rat neuropathic intermittent claudication model</title><title>Prostaglandins, leukotrienes and essential fatty acids</title><addtitle>Prostaglandins Leukot Essent Fatty Acids</addtitle><description>An orally active prostaglandin E1 analogue, OP-1206
α-CD improves walking dysfunction in the rat spinal stenosis model. Loxoprofen-Na, a non-steroidal anti-inflammatory drug, is used to relieve chronic pain in patients with lumbar spinal canal stenosis.
To determine whether the OP-1206
α-CD in combination with loxoprofen-Na could induce a greater therapeutical effect on walking dysfunction and spinal cord blood flow (SCBF) than OP-1206
α-CD treatment alone after chronic spinal stenosis in the rat.
Spinal stenosis was induced by placing two pieces of silicon rubber strips in the lumbar (L4 and L6) epidural space of rats. After surgery, walking function was measured using a treadmill apparatus and SCBF was measured using a laser-Doppler flow meter. Drugs were administered orally twice a day for 11 days from the day 3 post-surgery.
OP-1206
α-CD elicited a significant improvement of walking dysfunction on days 7 and 14 post-surgery and significantly increased spinal cord blood flow on day 15, whereas walking dysfunction and SCBF of rats treated with loxoprofen-Na alone remained unchanged. Combined treatment of OP-1206
α-CD with loxoprofen-Na did not provide additive therapeutical effect.
These results suggest that a significant improvement seen after OP-1206
α-CD treatment is primarily mediated by improvement of the local spinal cord blood flow. This effect is not ameliorated or potentiated by a combined treatment with loxoprofen-Na.</description><subject>Administration, Oral</subject><subject>alpha-Cyclodextrins</subject><subject>Alprostadil - administration & dosage</subject><subject>Alprostadil - analogs & derivatives</subject><subject>Alprostadil - pharmacology</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Cyclodextrins</subject><subject>Disease Models, Animal</subject><subject>Drug Therapy, Combination</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Intermittent claudication</subject><subject>Intermittent Claudication - drug therapy</subject><subject>Intermittent Claudication - physiopathology</subject><subject>Loxoprofen-Na</subject><subject>Male</subject><subject>OP-1206 α-CD</subject><subject>Phenylpropionates - administration & dosage</subject><subject>Phenylpropionates - pharmacology</subject><subject>Prostaglandins E, Synthetic - administration & dosage</subject><subject>Prostaglandins E, Synthetic - pharmacology</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Regional Blood Flow - drug effects</subject><subject>Spinal canal Stenosis</subject><subject>Spinal Cord - blood supply</subject><subject>Spinal cord blood flow</subject><subject>Spinal Stenosis - drug therapy</subject><subject>Spinal Stenosis - physiopathology</subject><subject>Vertebrates: endocrinology</subject><subject>Walking</subject><issn>0952-3278</issn><issn>1532-2823</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU1uFDEQhVuIiAyBI4C8AcGioWy3p7tXCA2BIEUECVhbbrvMGNz2xHYT5hAcJhfhTHRmRsmSVUml79XPe1X1hMIrCnT5-gv0gtWctd0L4C8BKPQ1vVctqOCsZh3j96vFLXJcPcz5BwAwSpsH1TFlPbSUt4vqz6m1qEsm0ZKYlPdboszogssFExpy8bmmDJbk73W9ekeuXFkTH3_HTYoWQ_1JkRjIlfI_XfhOzDbbKeji5p4LpKyRJFVIwCnFjSprp-f2PHZ0pWAoRHs1GafVTjBGg_5RdWSVz_j4UE-qb-9Pv67O6vOLDx9Xb89rzXtaaitAt9AhHxqGuuMGeo1tP4AQhjU9w26gxpolgOINt6BANdyYrukGYTgM_KR6vp87_3E5YS5ydFmj9ypgnLJsuRCctnwGxR7UKeac0MpNcqNKW0lB3uQgdznIG5MlcLnLQdJZ9_SwYBpGNHeqg_Ez8OwAqKyVt0kF7fIdJ9iSUiZm7s2ew9mOXw6TzNph0GhcmnOTJrr_nPIPmq2m1g</recordid><startdate>20031001</startdate><enddate>20031001</enddate><creator>Nakai, Katsuhiko</creator><creator>Takenobu, Yoshifumi</creator><creator>Takimizu, Hideyuki</creator><creator>Akimaru, Shinji</creator><creator>Ito, Hidenori</creator><creator>Maegawa, Hitoshi</creator><creator>Marsala, Martin</creator><creator>Katsube, Nobuo</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20031001</creationdate><title>Effects of orally administered OP-1206 α-CD with loxoprofen-Na on walking dysfunction in the rat neuropathic intermittent claudication model</title><author>Nakai, Katsuhiko ; Takenobu, Yoshifumi ; Takimizu, Hideyuki ; Akimaru, Shinji ; Ito, Hidenori ; Maegawa, Hitoshi ; Marsala, Martin ; Katsube, Nobuo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c391t-f50c708e3b42ec83d09ce79b055d2492e8b1dfd600a343f0a0a43dd848b5d30b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Administration, Oral</topic><topic>alpha-Cyclodextrins</topic><topic>Alprostadil - administration & dosage</topic><topic>Alprostadil - analogs & derivatives</topic><topic>Alprostadil - pharmacology</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Cyclodextrins</topic><topic>Disease Models, Animal</topic><topic>Drug Therapy, Combination</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Intermittent claudication</topic><topic>Intermittent Claudication - drug therapy</topic><topic>Intermittent Claudication - physiopathology</topic><topic>Loxoprofen-Na</topic><topic>Male</topic><topic>OP-1206 α-CD</topic><topic>Phenylpropionates - administration & dosage</topic><topic>Phenylpropionates - pharmacology</topic><topic>Prostaglandins E, Synthetic - administration & dosage</topic><topic>Prostaglandins E, Synthetic - pharmacology</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Regional Blood Flow - drug effects</topic><topic>Spinal canal Stenosis</topic><topic>Spinal Cord - blood supply</topic><topic>Spinal cord blood flow</topic><topic>Spinal Stenosis - drug therapy</topic><topic>Spinal Stenosis - physiopathology</topic><topic>Vertebrates: endocrinology</topic><topic>Walking</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nakai, Katsuhiko</creatorcontrib><creatorcontrib>Takenobu, Yoshifumi</creatorcontrib><creatorcontrib>Takimizu, Hideyuki</creatorcontrib><creatorcontrib>Akimaru, Shinji</creatorcontrib><creatorcontrib>Ito, Hidenori</creatorcontrib><creatorcontrib>Maegawa, Hitoshi</creatorcontrib><creatorcontrib>Marsala, Martin</creatorcontrib><creatorcontrib>Katsube, Nobuo</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Prostaglandins, leukotrienes and essential fatty acids</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nakai, Katsuhiko</au><au>Takenobu, Yoshifumi</au><au>Takimizu, Hideyuki</au><au>Akimaru, Shinji</au><au>Ito, Hidenori</au><au>Maegawa, Hitoshi</au><au>Marsala, Martin</au><au>Katsube, Nobuo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of orally administered OP-1206 α-CD with loxoprofen-Na on walking dysfunction in the rat neuropathic intermittent claudication model</atitle><jtitle>Prostaglandins, leukotrienes and essential fatty acids</jtitle><addtitle>Prostaglandins Leukot Essent Fatty Acids</addtitle><date>2003-10-01</date><risdate>2003</risdate><volume>69</volume><issue>4</issue><spage>269</spage><epage>273</epage><pages>269-273</pages><issn>0952-3278</issn><eissn>1532-2823</eissn><abstract>An orally active prostaglandin E1 analogue, OP-1206
α-CD improves walking dysfunction in the rat spinal stenosis model. Loxoprofen-Na, a non-steroidal anti-inflammatory drug, is used to relieve chronic pain in patients with lumbar spinal canal stenosis.
To determine whether the OP-1206
α-CD in combination with loxoprofen-Na could induce a greater therapeutical effect on walking dysfunction and spinal cord blood flow (SCBF) than OP-1206
α-CD treatment alone after chronic spinal stenosis in the rat.
Spinal stenosis was induced by placing two pieces of silicon rubber strips in the lumbar (L4 and L6) epidural space of rats. After surgery, walking function was measured using a treadmill apparatus and SCBF was measured using a laser-Doppler flow meter. Drugs were administered orally twice a day for 11 days from the day 3 post-surgery.
OP-1206
α-CD elicited a significant improvement of walking dysfunction on days 7 and 14 post-surgery and significantly increased spinal cord blood flow on day 15, whereas walking dysfunction and SCBF of rats treated with loxoprofen-Na alone remained unchanged. Combined treatment of OP-1206
α-CD with loxoprofen-Na did not provide additive therapeutical effect.
These results suggest that a significant improvement seen after OP-1206
α-CD treatment is primarily mediated by improvement of the local spinal cord blood flow. This effect is not ameliorated or potentiated by a combined treatment with loxoprofen-Na.</abstract><cop>Kidlington</cop><pub>Elsevier Ltd</pub><pmid>12907137</pmid><doi>10.1016/S0952-3278(03)00109-1</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0952-3278 |
| ispartof | Prostaglandins, leukotrienes and essential fatty acids, 2003-10, Vol.69 (4), p.269-273 |
| issn | 0952-3278 1532-2823 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73553173 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Administration, Oral alpha-Cyclodextrins Alprostadil - administration & dosage Alprostadil - analogs & derivatives Alprostadil - pharmacology Animals Biological and medical sciences Cyclodextrins Disease Models, Animal Drug Therapy, Combination Fundamental and applied biological sciences. Psychology Intermittent claudication Intermittent Claudication - drug therapy Intermittent Claudication - physiopathology Loxoprofen-Na Male OP-1206 α-CD Phenylpropionates - administration & dosage Phenylpropionates - pharmacology Prostaglandins E, Synthetic - administration & dosage Prostaglandins E, Synthetic - pharmacology Rats Rats, Wistar Regional Blood Flow - drug effects Spinal canal Stenosis Spinal Cord - blood supply Spinal cord blood flow Spinal Stenosis - drug therapy Spinal Stenosis - physiopathology Vertebrates: endocrinology Walking |
| title | Effects of orally administered OP-1206 α-CD with loxoprofen-Na on walking dysfunction in the rat neuropathic intermittent claudication model |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T11%3A25%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20orally%20administered%20OP-1206%20%CE%B1-CD%20with%20loxoprofen-Na%20on%20walking%20dysfunction%20in%20the%20rat%20neuropathic%20intermittent%20claudication%20model&rft.jtitle=Prostaglandins,%20leukotrienes%20and%20essential%20fatty%20acids&rft.au=Nakai,%20Katsuhiko&rft.date=2003-10-01&rft.volume=69&rft.issue=4&rft.spage=269&rft.epage=273&rft.pages=269-273&rft.issn=0952-3278&rft.eissn=1532-2823&rft_id=info:doi/10.1016/S0952-3278(03)00109-1&rft_dat=%3Cproquest_cross%3E73553173%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73553173&rft_id=info:pmid/12907137&rft_els_id=S0952327803001091&rfr_iscdi=true |